What is Leerink Partnrs’ Forecast for TNGX Q1 Earnings?

Tango Therapeutics, Inc. (NASDAQ:TNGX) – Leerink Partnrs issued their Q1 2025 earnings per share estimates for Tango Therapeutics in a research note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst A. Berens anticipates that the company will post earnings per share of ($0.32) for the quarter. The consensus estimate for Tango Therapeutics’ current full-year earnings is ($1.19) per share. Leerink Partnrs also issued estimates for Tango Therapeutics’ Q2 2025 earnings at ($0.36) EPS and Q4 2025 earnings at ($0.31) EPS.

Several other research analysts have also commented on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Tango Therapeutics in a research note on Thursday, December 5th. HC Wainwright reiterated a “buy” rating and set a $13.00 price objective on shares of Tango Therapeutics in a report on Friday, November 8th. Guggenheim dropped their target price on Tango Therapeutics from $18.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday, November 7th. Finally, B. Riley decreased their price target on Tango Therapeutics from $16.00 to $8.00 and set a “buy” rating for the company in a research note on Monday, November 11th. Eight analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $13.14.

Tango Therapeutics Stock Performance

Shares of Tango Therapeutics stock opened at $3.26 on Friday. Tango Therapeutics has a one year low of $2.59 and a one year high of $12.89. The company has a market capitalization of $350.19 million, a PE ratio of -2.76 and a beta of 0.80. The company has a 50-day simple moving average of $3.14 and a two-hundred day simple moving average of $6.12.

Insider Transactions at Tango Therapeutics

In related news, Director Mace Rothenberg purchased 10,000 shares of the business’s stock in a transaction on Monday, November 18th. The shares were bought at an average cost of $3.78 per share, with a total value of $37,800.00. Following the transaction, the director now owns 31,250 shares of the company’s stock, valued at approximately $118,125. This trade represents a 47.06 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Barbara Weber sold 9,778 shares of Tango Therapeutics stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $2.99, for a total value of $29,236.22. Following the transaction, the chief executive officer now owns 1,631,264 shares of the company’s stock, valued at $4,877,479.36. The trade was a 0.60 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 24,268 shares of company stock worth $72,561 over the last three months. 6.30% of the stock is currently owned by insiders.

Institutional Trading of Tango Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. State Street Corp lifted its holdings in Tango Therapeutics by 26.8% in the third quarter. State Street Corp now owns 2,318,208 shares of the company’s stock valued at $17,850,000 after acquiring an additional 489,949 shares during the period. Geode Capital Management LLC boosted its holdings in Tango Therapeutics by 11.6% during the third quarter. Geode Capital Management LLC now owns 1,368,262 shares of the company’s stock worth $10,538,000 after buying an additional 142,710 shares in the last quarter. Barclays PLC grew its position in Tango Therapeutics by 78.3% during the third quarter. Barclays PLC now owns 126,281 shares of the company’s stock valued at $972,000 after buying an additional 55,470 shares during the period. Dimensional Fund Advisors LP increased its holdings in Tango Therapeutics by 42.5% in the second quarter. Dimensional Fund Advisors LP now owns 335,913 shares of the company’s stock valued at $2,882,000 after buying an additional 100,257 shares in the last quarter. Finally, Verition Fund Management LLC acquired a new position in shares of Tango Therapeutics in the third quarter worth about $247,000. 78.99% of the stock is owned by institutional investors and hedge funds.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.